Cancer

Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)

REYKJAVIK, Iceland, May 13, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and…

8 months ago

Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update

SOLANA BEACH, Calif., May 13, 2024 (GLOBE NEWSWIRE) --  Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling…

8 months ago

Oncocyte to Announce First Quarter 2024 Financial Results

Conference Call and Webcast on Wednesday, May 15, 2024 at 1:30 p.m. PT / 4:30 p.m. ETIRVINE, Calif., May 13,…

8 months ago

Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference

NORCROSS, Ga., May 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target…

8 months ago

IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024

NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company advancing innovative gamma-delta T cell…

8 months ago

VITAS® Healthcare Names Four Leaders to Its Executive Team: Melad, Escueta, Dr. Loftis, Durkin

MIAMI, May 13, 2024 (GLOBE NEWSWIRE) -- VITAS Healthcare proudly announces the addition of four new leaders to its executive…

8 months ago

Reneo Pharmaceuticals and OnKure Announce Proposed Merger

Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure’s portfolio of novel precision medicines in oncology Combined…

8 months ago

Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024

AUSTIN, Texas, May 13, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted…

8 months ago

Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results

– Reports YCANTH® revenue of $3.2M for first quarter of 2024 – – Over 228 million lives now covered to date…

8 months ago

AlzeCure Reports Anti-Inflammatory Effects with NeuroRestore ACD856 with Relevance to Alzheimer’s Leading to New Patent Application

STOCKHOLM, SWEDEN / ACCESSWIRE / May 13, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical…

8 months ago